532300 Stock Overview
A pharmaceutical and biotech company, manufactures and trades pharmaceuticals, medicinal, botanical, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Wockhardt Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,230.95 |
| 52 Week High | ₹1,334.55 |
| 52 Week Low | ₹323.30 |
| Beta | 1.51 |
| 11 Month Change | 15.32% |
| 3 Month Change | 16.29% |
| 1 Year Change | 263.92% |
| 33 Year Change | 186.43% |
| 5 Year Change | 377.58% |
| Change since IPO | 530.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| 532300 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 5.1% | 0.5% | 0.5% |
| 1Y | 263.9% | 42.5% | 27.5% |
Return vs Industry: 532300 exceeded the Indian Pharmaceuticals industry which returned 42.5% over the past year.
Return vs Market: 532300 exceeded the Indian Market which returned 27.5% over the past year.
Price Volatility
| 532300 volatility | |
|---|---|
| 532300 Average Weekly Movement | 6.9% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 532300 has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: 532300's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1967 | 2,386 | Murtaza Khorakiwala | www.wockhardt.com |
Wockhardt Limited, a pharmaceutical and biotech company, manufactures and trades pharmaceuticals, medicinal, botanical, and chemical products in India, the United States, the United Kingdom, Switzerland, Ireland, Russia, Europe, and internationally. The company develops qualified infectious diseases products comprising WCK5222, which is in phase 3 clinical trial for the treatment of sepsis and hospital/ventilator associated pneumonia; WCK 4282, which is in phase 3 clinical trial for ESBL infections; WCK 6777, which is phase 1 to treat gram negative infections; and WCK 4873, which is phase 3 clinical trial for community-acquired bacterial pneumonia. It also offers rapid and long-acting insulin analogues, concentrated insulins, GLP1 analogues, haemopoietins, biobetters and novel products, and delivery devices.
Wockhardt Limited Fundamentals Summary
| 532300 fundamental statistics | |
|---|---|
| Market cap | ₹200.39b |
| Earnings (TTM) | -₹2.88b |
| Revenue (TTM) | ₹29.81b |
6.7x
P/S Ratio-69.6x
P/E RatioIs 532300 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 532300 income statement (TTM) | |
|---|---|
| Revenue | ₹29.81b |
| Cost of Revenue | ₹12.73b |
| Gross Profit | ₹17.08b |
| Other Expenses | ₹19.96b |
| Earnings | -₹2.88b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -17.73 |
| Gross Margin | 57.30% |
| Net Profit Margin | -9.66% |
| Debt/Equity Ratio | 58.0% |
How did 532300 perform over the long term?
See historical performance and comparison